As of mid-2022, there are a number of treatments for COVID-19 that have been either approved by the FDA or have been authorized for emergency use (EUA).
On December 8, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld, a monoclonal antibody combination of tixagevimab and cilgavimab.
Recommended questions lymphoma patients, survivors, and caregivers can ask their healthcare provider.
The Lymphoma Research Foundation (LRF) encourages patients, survivors, and their caregivers to take information and questions back to their individual health care providers as a way of creating a dialogue and partnership about their lymphoma and treatment.
People who have compromised immune systems may benefit from an additional dose to make sure they have enough protection against COVID-19.
On July 27, 2021, the Centers for Disease Control and Prevention (CDC) updated its Guidance for Fully Vaccinated people to include recommendations for those in the same household as immunocompromised people, including those with blood cancer.
With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.
LRF Urges CDC to Prioritize Blood Cancer Patients for COVID-19 Vaccine VISIT THE COVID-19 LEARNING CENTER FOR…
A lymphoma diagnosis can be challenging to cope with at any time, but the current…
On December 11 and 18, 2020 the U.S. Food and Drug Administration (FDA) issued two…